Mercado global de biópsia líquida baseada em vesículas extracelulares – Tendências do setor e previsão para 2031

Análise e tamanho do mercado de biópsia líquida baseada em vesículas extracelulares

O mercado da biópsia líquida baseada em vesículas extracelulares (EVs) está a registar um crescimento robusto, impulsionado por uma procura crescente por métodos de diagnóstico não invasivos e pelos avanços nas tecnologias de biópsia líquida. As vesículas extracelulares, incluindo exossomas e microvesículas, têm ganho destaque como fontes valiosas de biomarcadores para diversas doenças, como o cancro e as doenças neurodegenerativas. O mercado está a assistir a um aumento das atividades de investigação e desenvolvimento, colaborações e parcerias estratégicas entre os principais participantes da indústria, promovendo a inovação em soluções de biópsia líquida baseadas em VE. A crescente prevalência do cancro, juntamente com uma crescente consciencialização sobre o potencial da biópsia líquida na detecção precoce e na monitorização de doenças, está a impulsionar ainda mais o crescimento do mercado.                                

A Data Bridge Market Research analisa que o mercado global de biópsia líquida baseada em vesículas extracelulares, que foi de 94,88 milhões de dólares em 2023, deverá atingir até 444,70 milhões de dólares até 2031, e deverá passar por um CAGR de 21 ,3% durante o período de previsão. “Kits e ensaios” domina o segmento de oferta do mercado devido à crescente adoção de kits de isolamento, ensaios e acessórios. Além dos insights sobre cenários de mercado, tais como valor de mercado, taxa de crescimento, segmentação, cobertura geográfica e grandes players, os relatórios de mercado com curadoria da Data Bridge Market Research incluem também análise especializada aprofundada, epidemiologia de pacientes, análise de pipeline, análise de preços, e quadro regulamentar.

Âmbito do relatório e segmentação de mercado

Definição de mercado

A biópsia líquida baseada em vesículas extracelulares (EVs) é uma abordagem de diagnóstico de ponta que envolve o isolamento e a análise de vesículas extracelulares, como exossomas e microvesículas, de biofluidos como sangue, urina ou líquido cefalorraquidiano. Estas vesículas, libertadas pelas células no meio extracelular, contêm uma carga diversificada de proteínas, ácidos nucleicos e lípidos que refletem a sua célula de origem. Utilizando técnicas de biópsia líquida, os VE são extraídos de forma não invasiva, oferecendo uma fonte valiosa de biomarcadores para diversas doenças, especialmente o cancro. A análise do conteúdo de VE fornece informações sobre as assinaturas moleculares e genéticas de condições patológicas, permitindo a deteção precoce, a monitorização da progressão da doença e a avaliação da resposta ao tratamento.

Dinâmica global do mercado de biópsia líquida baseada em vesículas extracelulares

Motoristas

• Procura crescente por natureza não invasiva de biópsia líquida

A natureza não invasiva da biópsia líquida baseada em vesículas extracelulares (EVs) é um motor significativo para o crescimento do mercado. Ao contrário das biópsias de tecidos tradicionais, as biópsias líquidas, que utilizam VE de biofluidos como sangue ou urina, oferecem uma abordagem menos invasiva e mais amigável para o paciente para o diagnóstico e monitorização de doenças. Esta característica é particularmente atraente para indivíduos que podem ser avessos ou inelegíveis para procedimentos cirúrgicos.

• Avanços nas tecnologias de biópsia líquida

Os avanços contínuos nas tecnologias de biópsia líquida, incluindo técnicas melhoradas de isolamento e caracterização de vesículas extracelulares, estão a impulsionar o crescimento do mercado. As inovações tecnológicas contribuem para aumentar a sensibilidade e a especificidade na deteção de biomarcadores associados a doenças nos VE, tornando estes métodos de biópsia líquida cada vez mais fiáveis ​​​​e aplicáveis ​​​​a uma gama mais ampla de doenças, incluindo cancro e doenças neurodegenerativas .

• Aumento da prevalência do cancro

The increasing prevalence of cancer globally is a major driver for the adoption of extracellular vesicles based liquid biopsy. As liquid biopsies, including EV-based approaches, become instrumental in the early detection and monitoring of cancer, the growing incidence of the disease fuels the demand for more effective and less invasive diagnostic methods, supporting the expansion of the market.

• Growing Investment for Healthcare Facilities

Surging focus towards improving the condition of healthcare facilities and improving the overall healthcare infrastructure another important factor fostering the growth of the market. Rising number of partnerships and strategic collaborations between the public and private players pertaining to funding and application of new and improved technology is further creating lucrative market opportunities.  

Opportunities

• Growing Emphasis on Personalized Medicine

The global shift toward personalized medicine and targeted therapies is boosting the demand for precise and molecularly-informed diagnostic tools. Extracellular vesicles based liquid biopsy provides a means to capture the dynamic molecular profile of diseases, supporting the trend toward personalized healthcare strategies. The ability to tailor treatments based on the specific genetic and molecular characteristics of each patient contributes to the market's growth as a crucial component of the evolving healthcare landscape.

• Expanded application in various diseases

The extracellular vesicles (EVs) based liquid biopsy market has the opportunity to expand its application beyond cancer to a broader spectrum of diseases. As research progresses, there is potential to identify and validate EV biomarkers for neurodegenerative disorders, cardiovascular diseases, and other conditions. Diversifying the application of EV-based liquid biopsy could significantly broaden the market's reach and impact on diagnostics and personalized medicine.

Restraints

• Standardization and lack of consensus

A major restraint in the extracellular vesicles (EVs) based liquid biopsy market is the lack of standardized isolation and analysis protocols. Variability in methodologies and a lack of consensus on best practices can lead to inconsistent results and hinder the widespread adoption of EV-based liquid biopsy. Establishing standardized procedures is crucial for ensuring the reliability and reproducibility of results across different laboratories and settings.

• Regulatory challenges and approval processes

The regulatory landscape for liquid biopsy technologies, including those based on extracellular vesicles, is evolving. Regulatory approval processes may vary across regions, and achieving standardized guidelines can be challenging. Stringent regulatory requirements and a lack of clear pathways for approval may slow down the commercialization and widespread adoption of EV-based liquid biopsy methods.

Challenges

• Ethical and privacy concerns

The use of liquid biopsy technologies, including those based on extracellular vesicles, raises ethical and privacy concerns. Issues related to the ownership of biological samples, informed consent, and the secure handling of sensitive patient data must be addressed. Ensuring compliance with ethical standards and regulatory frameworks, particularly as these technologies become more widespread, is essential for building trust among patients and stakeholders in the global healthcare community.

• Sample standardization and quality control

Ensuring consistent and standardized collection, processing, and storage of biofluid samples for extracellular vesicles (EVs) based liquid biopsy poses a significant challenge. Variability in sample handling can introduce biases and impact the reproducibility and reliability of results. Establishing standardized protocols for sample preparation and implementing stringent quality control measures are crucial for overcoming this challenge.

This extracellular vesicles based liquid biopsy market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the extracellular vesicles based liquid biopsy market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In January 2022, QIAGEN announced its new Biotech Grants program winners, an initiative driven by the company's commitment to building strong partnerships with biotechnology and pharma businesses and helping them succeed in the market. This has helped the company in revenue growth
• In January 2022, Exact Sciences Corporation announced the acquisition of Prevention Genetics, a genetic testing laboratory, to complement its advanced cancer diagnostics portfolio and support its entrance into hereditary cancer testing (HCT)

Global Extracellular Vesicles Based Liquid Biopsy Market Scope

The extracellular vesicles based liquid biopsy market is segmented on the basis of offering, technology, workflow and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Offering

• Kits and Assays
• Services
• Instruments

Technology                                                                     

• Isolation
• Analysis

Workflow

• Sample Preparation
• Sequencing
• Data Analysis

End user

• Academic and Research Institutes
• Clinical Laboratories
• Pharmaceutical and Biotechnology Companies

Global Extracellular Vesicles Based Liquid Biopsy Market Regional Analysis/Insights

The extracellular vesicles based liquid biopsy market is analyzed and market size insights and trends are provided by country, offering, technology, workflow and end user as referenced above.

The countries covered in the market report are U.S., Canada, Mexico, Brazil, Argentina, the rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, and rest of the Middle East and Africa.

North America is expected to dominate the market due to the rise of large medical device manufacturers, the presence of major market players and increased technological advancement in the region.

Asia-Pacific is expected to observe significant amount of growth in the market due to the rapid necessity for telemedicine and healthcare support. Moreover, the modernization and development in telecommunication are further anticipated to propel the growth of the extracellular vesicles based liquid biopsy market in the region in the coming years.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure growth Installed base and New Technology Penetration

The extracellular vesicles based liquid biopsy market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for extracellular vesicles based liquid biopsy market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the extracellular vesicles based liquid biopsy market. The data is available for historic period 2010-2020.

Competitive Landscape and Extracellular vesicles based liquid biopsy Market Share Analysis

O panorama competitivo do mercado de biópsia líquida baseada em vesículas extracelulares fornece detalhes por concorrente. Os detalhes incluídos são a visão geral da empresa, finanças da empresa, receitas geradas, potencial de mercado, investimento em investigação e desenvolvimento, novas iniciativas de mercado, presença global, localizações e instalações de produção, capacidades de produção, pontos fortes e fracos da empresa , lançamento de produto, largura e amplitude do produto, aplicação domínio. Os dados acima fornecidos estão apenas relacionados com o foco das empresas relacionado com o mercado da biópsia líquida baseada em vesículas extracelulares.

Alguns dos principais players que operam no mercado da biópsia líquida baseada em vesículas extracelulares são:

• Bio-Techne Corporation (EUA)
• Thermo Fisher Scientific Inc.
• QIAGEN NV (Holanda)
• Exossomo Diagnostics, Inc.
• (EUA)
• System Biosciences, LLC (EUA)
• (EUA)
• Malvern Panalytical Ltd. (Reino Unido)
• Norgen Biotek Corp. (Canadá)
• Hitachi Chemical Co., Ltd. (Japão)
• Lonza Group Ltd. (Suíça)
• Codiak BioSciences, Inc.
• NX Pharmagen (Coreia do Sul)
• Stemcell Technologies Inc. (Canadá)
• Aruna Bio (EUA)
• Evomic Science LLC (EUA)
• Izon Science Ltd. (Nova Zelândia)
• Exovita Biociências (EUA)
• Anergis SA (Suíça)
• System Biosciences (SBI) (EUA)

SKU-70526